AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Aptamer D3P-21

Summary

Aptamer spezifisch für kastrationsresistenten Prostatakrebs.

Technology Benefits

High affinity Aptamer
Easy to produce
High plasma half-life
Excellent tumor selectivity

Technology Application

The Aptamer of the present invention may be used for diagnostic or therapeutic purposes. In particular when coupled to a drug, the Aptamer may be used in analogy to an antibody-drug-conjugate.

Detailed Technology Description

The inventors used an orthotopic xenograft mouse model to perform an in vivo selection in order to identify an aptamer that selectively binds to cells of a hormone refractory prostate tumour. Several rounds of selection starting from a DNA library yielded an aptamer that binds to tumour tissue in vivo and to PC3 cells in vitro. The Aptamer is characterized in a PEGylation pattern that stabilizes the Aptamer and prolongs plasma half-life.

Type of Cooperation

Licensing

Application Date

21/01/2019 00:00:00

Others

Patent application

ID No.

5463

Country/Region

Germany

For more information, please click Here